Biologics/Update·FDA Vaccines, Blood & Biologics

Blood Grouping Regents, BL 101728-34;103292; 125848-125855

MediumPublished May 22, 2026· AI-analyzed May 24, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

The FDA updated or issued documentation regarding Blood Grouping Regents under BL numbers 101728-34, 103292, and 125848-125855 for testing human red blood cells via room temperature saline tube tests.

Who it affects

This affects manufacturers of blood grouping reagents, clinical laboratory personnel performing blood typing, and regulatory affairs professionals managing Biologics License Applications (BLAs) for immunohematology products.

Why it matters

The listing of specific Biologics License numbers associated with a standardized testing method (room temperature saline tube test) suggests a maintenance of regulatory status or a technical update for these reagents. For compliance departments, this underscores the necessity of maintaining precise methodology documentation for diagnostic reagents used in pre-transfusion or diagnostic settings. The source does not specify if this is a new approval or an amendment, but the specificity of the test type indicates strict adherence to validated protocols is required.

Practical takeaway

Regulatory and QA teams should ensure that standard operating procedures (SOPs) for these reagents align strictly with the room temperature saline tube test method. Internal audits should verify that the specific Biologics License (BL) numbers listed are correctly captured in current facility inventory and labeling systems.

FDA source material

Blood Grouping Regents, BL 101728-34;103292; 125848-125855<br> Reagent is used for testing human red blood cells by the room temperature saline tube test

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.